Veracyte saw its IBD SmartSelect Composite Rating jump to 96 Tuesday, up from 92 the day before.
The new rating is a sign the stock is outpacing 96% of all stocks when it comes to the most important stock-picking criteria. The top-performing stocks tend to have a 95 or better grade as they start a significant move so be sure to keep that in mind when looking for the best stocks to buy and watch.
Veracyte is trading about 2% above a 41.43 entry from a ascending base.
Looking For The Best Stocks To Buy And Watch? Start Here
The stock has an 81 EPS Rating, which means its recent quarterly and annual earnings growth is outpacing 81% of all stocks.
Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.
The company posted a 94% EPS gain for Q3. Sales growth increased 29%, up from 27% in the prior report. The company has now posted accelerating growth in each of the last two reports.
Veracyte holds the No. 1 rank among its peers in the Medical-Research Equipment/Services industry group. Natera and Medpace Holdings are also among the group's highest-rated stocks.
